Trial Profile

Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 16 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Seclidemstat (Primary)
Indications Carcinoma; Endometrial cancer; Ovarian cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
16 Nov 2021 Planned initiation date changed from 1 Oct 2021 to 31 Dec 2021.
14 Sep 2021 Planned initiation date changed from 1 Aug 2021 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com